Reveal Pharma

4:30 PM - 4:45 PM (EDT), Monday, June 5, 2023 ・ Session Room 104A
Reveal is a clinical stage company positioned to transform medical insight. Our first in class imaging drugs address two major needs:
1) safer, gadolinium-free MR imaging
2) imaging fibrogenesis (PET and MRI)

Gadolinium accumulates in the brain and body of every person using current MRI contrast agents (GBCAs); GBCAs also pollute earth's surface waters. Despite an FDA boxed warning there is no alternative for 40 million scans per year. Reveal’s RVP-001 is based on biocompatible manganese and is designed to seamlessly replace general purpose GBCAs.
Fibrotic disease contributes to 40% of US deaths but current methods cannot accurately assess early disease, active disease, or early response to treatment. Reveal’s molecular imaging agents target lysol oxidase, a byproduct of fibrogenesis, promising unprecedented insight for diagnosis, patient stratification, and early readout of response to therapy.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Tools/Drug Development Support Tech
Lead Product in Development:
RVP-001 - first gadolinium-free general purpose MRI contrast agent
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Reveal Pharma